Virax Biolabs Group Limited an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, today highlighted key milestones, achievements and clinical progress while outlining its strategic priorities for 2026 in a letter to shareholders and investors.
AstraZeneca’s IMFINZI® in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
For the millions of people worldwide living with severe forms of epilepsy, some do not respond to medication and it can be difficult to find lasting relief. Patients with a severe epileptic condition called focal treatment-resistant epilepsy (FTRE) could experience seizures that start in a specific part of their brain and continue to occur despite significant and appropriate efforts to control them with medication.
Attendees at this year's American Orthopedic Foot and Ankle Society's Annual Meeting in Savannah, Ga., will be the first to see Medline UNITE Foot & Ankle's new FORCECORD™ Midsubstance Achilles Repair System and DEXLOCK® Knotless Double Row Achilles Repair System.
In a category long dominated by legacy brands and artificial additives, a new national survey reveals a powerful shift: U.S. pediatricians overwhelmingly prefer the ingredient profiles in Genexa’s pediatric pain and fever liquid medicines over those in Children’s Tylenol® top-selling comparable products. Genexa is the first clean medicine company, revolutionizing the over-the-counter (OTC) medicine aisle by making medicine with the same effective active ingredients as the leading brands, but without any artificial additives.
Regeneron Pharmaceuticals, Inc. and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. In the trial, Dupixent® (dupilumab) outperformed Xolair® (omalizumab) on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints.
UroGen engages in the development and commercialization of solutions for specialty cancers. The Company’s lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer.
Researchers at the Feinstein Institutes for Medical Research have developed a groundbreaking new method for vagus nerve stimulation (VNS) that offers unprecedented control over nerve fiber activation, paving the way for more effective and personalized treatments for a wide range of chronic diseases.
Obesity affects over a third of the global population and is a major risk factor for numerous chronic diseases. To find better therapies to fight obesity and its related health problems, researchers at Northwell Health’s Feinstein Institutes for Medical Research are investigating a promising new approach in which vagus nerve stimulation (VNS) interacts with growth factor-β (TGF-β) signaling, a driver and suppressor of metabolic function.
Piramal Pharma Limited a leading global pharmaceuticals and wellness company, in conjunction with the 2025 SelectUSA Investment Summit, commits to a $90M investment plan towards expanding two of the Company's US facilities. These expansions are in response to ongoing demand from US customers, in support of the trend towards US onshoring of drug supply, and in line with Piramal Pharma's overall belief in the value and benefits of US-based innovation.